Navigation Links
deCODE Receives California Clinical Laboratory License
Date:2/19/2009

n the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM), for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service and new Cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effects of the transfer of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market and the potential delisti
'/>"/>

SOURCE deCODE genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
2. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
3. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
4. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
5. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
6. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
7. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
8. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
9. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
10. Major deCODE-led Study Underscores Role of the Brain in Obesity
11. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 What can ... Which areas are going to grow at the fastest ... potential revenues to 2025, assessing data, trends, opportunities and ... provides 176 tables, charts, and graphs. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:7/30/2015)...  Lannett Company, Inc. (NYSE: LCI ) today ... Genuity 35th Annual Growth Conference on Wednesday, August 12, ... Hotel.  A webcast of the presentation ... encouraged to visit the web site at least 10 ... register, download and install any necessary software.  The presentation ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:7/30/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. ... Ginette Collazo, a 15 year veteran of helping drug, biologic and device firms ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 2015 , ... The Clinical Data Interchange Standards Consortium (CDISC), ... that data standards for clinical research in the areas of Schizophrenia, Hepatitis C ... These three Therapeutic Area (TA) standards were developed per the CDISC global, consensus-based ...
(Date:7/30/2015)... ... ... a healthy head of hair and a feeling of confidence is a powerful one for ... a devastating impact on the daily life of a person. From increased anxiety to ... loss are not to be taken lightly. , The skilled staff at Parsa Mohebi Hair ...
(Date:7/30/2015)... CATHERAL CITY, California (PRWEB) , ... July 30, 2015 , ... ... of substance abuse, clients at Serenity Palms Drug Addiction Treatment Center have created an ... Springs just lost one of its most beloved residents, Rocky Hudson . Hudson ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: